undamentalytics Newsletter
Sign in

PTC Therapeutics, Inc. income statement

In fiscal 2025, PTC Therapeutics, Inc. reported revenue of $1.73bn, up 114.5% on the year before, operating income of $867m (a 50.1% margin) and net income of $683m, or $7.78 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue10534352537831942653073815396999388071,7311,156
Cost of revenue——————51312———————
Gross profit——————190252295———————
Research and development59465580122118117172257478541651667534455439
Selling, general and administrative—————97121154203245286326333301347344
General and administrative1615254582———————————
Operating income31−27−45−99−167−132−64−116−241−432−374−447−440−303867148
Income before tax29−26−52−98−170−142−78−128−240−403−518−587−696−363697−85
Income tax−2——−5011−012356−28−7001421
Net income31−26−52−94−170−142−79−128−252−438−524−559−627−363683−106
Diluted EPS$4.55$42.50−$5.18−$2.97−$5.07−$4.17−$2.02−$2.75−$4.27−$6.64−$7.43−$7.79−$8.37−$4.73$7.78−$1.18
Diluted shares (average)—17m13m32m34m34m39m47m59m66m70m72m75m77m88m90m
EBITDA33−24−43−97−164−129−47−90−209−388−310−319−203−227906209

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACAD vs PTCTLKFT vs PTCTMDGL vs PTCT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from PTC Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to PTC Therapeutics, Inc.